Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers

International Journal of Cancer

Volumn 138, Issue 5, 2016, Pages 1199-1206

  Burdelski, Christoph ^a   Kleinhans, Sandra ^a   Kluth, Martina ^a   Hube Magg, Claudia ^a   Minner, Sarah ^a   Koop, Christina ^a   Graefen, Markus ^a   Heinzer, Hans ^a   Tsourlakis, Maria Christina ^a   Wilczak, Waldemar ^a   Marx, Andreas ^a   Sauter, Guido ^a   Wittmer, Corinna ^a   Huland, Hartwig ^a   Simon, Ronald ^a   Schlomm, Thorsten ^a   Steurer, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AZGP1; IHC; prognosis; prostate cancer; tissue microarray; TPMRSS2:ERG fusion

Indexed keywords

ALPHA2 GLYCOPROTEIN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ZINC BINDING ALPHA 2 GLYCOPROTEIN; AZGP1 PROTEIN, HUMAN; CARRIER PROTEIN; ERG PROTEIN, HUMAN; GLYCOPROTEIN; PTEN PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME DELETION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; BLOOD; GENE DELETION; GENE FUSION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; CARRIER PROTEINS; GENE DELETION; GENE FUSION; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TRANS-ACTIVATORS;

EID: 84955648718     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29860     Document Type: Article

References (44)

1. Jemal A, Ward E, Wu X, et al., Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005; 14: 590-5.
2. Burgi W, Schmid K., Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem 1961; 236: 1066-74.
3. Frenette G, Dube JY, Lazure C, et al., The major 40-kDa glycoprotein in human prostatic fluid is identical to Zn-alpha 2-glycoprotein. Prostate 1987; 11: 257-70.
4. Bing C, Bao Y, Jenkins J, et al., Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 2004; 101: 2500-5.
5. Tada T, Ohkubo I, Niwa M, et al., Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 1991; 39: 1221-6.
6. Ohkubo I, Niwa M, Takashima A, et al., Human seminal plasma Zn-alpha 2-glycoprotein: its purification and properties as compared with human plasma Zn-alpha 2-glycoprotein. Biochim Biophys Acta 1990; 1034: 152-6.
7. Henshall SM, Horvath LG, Quinn DI, et al., Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 1420-4.
8. Diez-Itza I, Sanchez LM, Allende MT, et al., Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 1993; 29A: 1256-60.
9. Dubois V, Delort L, Mishellany F, et al., Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res 2010; 30: 2919-25.
10. Freije JP, Fueyo A, Uria J, et al., Human Zn-alpha 2-glycoprotein cDNA cloning and expression analysis in benign and malignant breast tissues. FEBS Lett 1991; 290: 247-9.
11. Abdul-Rahman PS, Lim BK, Hashim OH., Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis 2007; 28: 1989-96.
12. Gagnon S, Tetu B, Dube JY, et al., Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases. Am J Pathol 1990; 136: 1147-52.
13. Yip PY, Kench JG, Rasiah KK, et al., Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011; 71: 1638-45.
14. Lapointe J, Li C, Higgins JP, van de Rijn M, et al., Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-6.
15. Descazeaud A, de la Taille A, Allory Y, et al., Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006; 66: 1037-43.
16. O'Hurley G, O'Grady A, Smyth P, et al., Evaluation of zinc-alpha-2-glycoprotein and proteasome subunit beta-type 6 expression in prostate cancer using tissue microarray technology. Appl Immunohistochem Mol Morphol, in press.
17. Mills J, Oliver A, Sherwin JC, et al., Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer. Pathology 2012; 44: 513-8.
18. Severi G, Fitzgerald LM, Muller DC, et al., A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease-Severi-2014-Cancer Medicine-Wiley Online Library. Cancer Med 2014; 3: 1266-74.
19. Mottet N, Bellmunt J, Bolla M, et al., Guía de la EAU sobre el cáncer de prõstata. Parte II: tratamiento del cáncer de prõstata avanzado, recidivante y resistente a la castraciõn. Actas Urologicas Españolas 2011; 35: 565-79.
20. Schlomm T, Iwers L, Kirstein P, et al., Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-8.
21. Kononen J, Bubendorf L, Kallioniemi A, et al., Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
22. Weischenfeldt J, Simon R, Feuerbach L, et al., Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23: 159-70.
23. Minner S, Enodien M, Sirma H, et al., ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-88.
24. Burkhardt L, Fuchs S, Krohn A, et al., CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013; 73: 2795-805.
25. Kluth M, Hesse J, Heinl A, et al., Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol 2013; 26: 975-83.
26. Krohn A, Diedler T, Burkhardt L, et al., Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181: 401-12.
27. Krohn A, Seidel A, Burkhardt L, et al., Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol 2013; 231: 130-41.
28. Dancau A-M, Simon R, Mirlacher M, et al., Tissue microarrays. Methods in Molecular Biology (Clifton, NJ) 2010; 576: 49-60.
29. Simon R, Mirlacher M, Sauter G., Immunohistochemical analysis of tissue microarrays. Methods Mol Biol (Clifton, NJ) 2010; 664: 113-26.
30. Berger MF, Lawrence MS, Demichelis F, et al., The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
31. Taylor BS, Schultz N, Hieronymus H, et al., Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
32. Lapointe J, Li C, Giacomini CP, et al., Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67: 8504-10.
33. Hale LP, Price DT, Sanchez LM, et al., Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001; 7: 846-53.
34. Tennstedt P, Köster P, Brüchmann A, et al., The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 2012; 40: 261-8.
35. Byrne JC, Downes MR, O'Donoghue N, et al., 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8: 942-57.
36. Zadra G, Photopoulos C, Loda M., The fat side of prostate cancer. Biochim Biophys Acta 2013; 1831: 1518-32.
37. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
38. Massoner P, Kugler KG, Unterberger K, et al., Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS One 2013; 8: e55207
39. Grupp K, Kohl S, Sirma H, et al., Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 2013; 26: 733-42.
40. Grupp K, Diebel F, Sirma H, et al., SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate 2013; 73: 1690-8.
41. Choucair K, Ejdelman J, Brimo F, et al., PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012; 12: 543
42. Wang Y, He X, Ngeow J, et al., GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet 2012; 21: 569-76.
43. Bohm M, Locke WJ, Sutherland RL, et al., A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene 2009; 28: 3847-56.
44. Nakagawa T, Kollmeyer TM, Morlan BW, et al., A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008; 3: e2318